Tomsitz, D.; Schlaak, M.; Zierold, S.; Pesch, G.; Schulz, T.U.; Müller, G.; Zecha, C.; French, L.E.; Heinzerling, L.
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. Cancers 2022, 14, 3282.
https://doi.org/10.3390/cancers14133282
AMA Style
Tomsitz D, Schlaak M, Zierold S, Pesch G, Schulz TU, Müller G, Zecha C, French LE, Heinzerling L.
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. Cancers. 2022; 14(13):3282.
https://doi.org/10.3390/cancers14133282
Chicago/Turabian Style
Tomsitz, Dirk, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, and Lucie Heinzerling.
2022. "Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma" Cancers 14, no. 13: 3282.
https://doi.org/10.3390/cancers14133282
APA Style
Tomsitz, D., Schlaak, M., Zierold, S., Pesch, G., Schulz, T. U., Müller, G., Zecha, C., French, L. E., & Heinzerling, L.
(2022). Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. Cancers, 14(13), 3282.
https://doi.org/10.3390/cancers14133282
